Cargando…

Correction: Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663080/ https://www.ncbi.nlm.nih.gov/pubmed/34887264 http://dx.doi.org/10.1136/jitc-2021-003850corr1

Ejemplares similares

Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
por: van Diest, Eline, et al.
Publicado: (2021)

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers
por: van Diest, Eline, et al.
Publicado: (2023)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Mammalian Display Platform for the Maturation of Bispecific TCR-Based Molecules
por: Dilchert, Janine, et al.
Publicado: (2022)

Correction: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
Publicado: (2022)

Correction: Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1
Publicado: (2023)

Immunotherapeutic progress and application of bispecific antibody in cancer
por: Kang, Jingyue, et al.
Publicado: (2022)

Editorial: Understanding Gamma Delta T Cell Multifunctionality - Towards Immunotherapeutic Applications
por: Gustafsson, Kenth, et al.
Publicado: (2020)

Correction to: Gamma-delta (γδ) T cells: friend or foe in cancer development?
por: Zhao, Yijing, et al.
Publicado: (2018)

Human TCR-gamma+/delta+, CD8+ T lymphocytes recognize tetanus toxoid in an MHC-restricted fashion
Publicado: (1989)

Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8(+) T‑cells from GzmB mediated self‑destruction
por: Zangari, Brendan, et al.
Publicado: (2022)

Key Features of Gamma-Delta T-Cell Subsets in Human Diseases and Their Immunotherapeutic Implications
por: Lawand, Myriam, et al.
Publicado: (2017)

Gab2 and Gab3 Redundantly Suppress Colitis by Modulating Macrophage and CD8(+) T-Cell Activation
por: Wang, Zhengqi, et al.
Publicado: (2019)

A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release
por: Xu, Yiyang, et al.
Publicado: (2018)

Surface expression of a T cell receptor beta (TCR-beta) chain in the absence of TCR-alpha, -delta, and -gamma proteins
Publicado: (1991)

T cells with gamma/delta T cell receptors (TCR) of intestinal type are preferentially expanded in TCR-alpha-deficient lpr mice
Publicado: (1995)

Author Correction: Phosphoinositides regulate the TCR/CD3 complex membrane dynamics and activation
por: Chouaki Benmansour, Nassima, et al.
Publicado: (2020)

Correction: GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
Publicado: (2021)

Correction: Human and Murine Clonal CD8+ T Cell Expansions Arise during Tuberculosis Because of TCR Selection
Publicado: (2015)

CD3+CD16+NK1.1+B220+ large granular lymphocytes arise from both alpha- beta TCR+CD4-CD8- and gamma-delta TCR+CD4-CD8- cells
Publicado: (1994)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Correction: Tripartite Motif-Containing Protein 30 Modulates TCR-Activated Proliferation and Effector Functions in CD4(+) T Cells
Publicado: (2014)

TCR-mimic bispecific antibodies to target the HIV-1 reservoir
por: Sengupta, Srona, et al.
Publicado: (2022)

Correction: NSOM/QD-Based Direct Visualization of CD3-Induced and CD28-Enhanced Nanospatial Coclustering of TCR and Coreceptor in Nanodomains in T Cell Activation
por: Zhong, Liyun, et al.
Publicado: (2010)

Correction: NSOM/QD-Based Direct Visualization of CD3-Induced and CD28-Enhanced Nanospatial Coclustering of TCR and Coreceptor in Nanodomains in T Cell Activation
por: Zhong, Liyun, et al.
Publicado: (2010)

Correction: NSOM/QD-Based Direct Visualization of CD3-Induced and CD28-Enhanced Nanospatial Coclustering of TCR and Coreceptor in Nanodomains in T Cell Activation
por: Zhong, Liyun, et al.
Publicado: (2010)

Correction: Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
Publicado: (2021)

Correction: Transduction of SIV-Specific TCR Genes into Rhesus Macaque CD8(+) T Cells Conveys the Ability to Suppress SIV Replication
por: Barsov, Eugene V., et al.
Publicado: (2018)

Correction to: Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
por: Yuan, Juanjuan, et al.
Publicado: (2021)

Correction: CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
por: Niu, Jiahua, et al.
Publicado: (2023)

Differential expression of CD45RO (UCHL1) and its functional relevance in two subpopulations of circulating TCR-gamma/delta+ lymphocytes
Publicado: (1990)

Characterization of a Novel Single-Chain Bispecific Antibody for Retargeting of T Cells to Tumor Cells via the TCR Co-Receptor CD8
por: Michalk, Irene, et al.
Publicado: (2014)

Correction: Bacillus anthracis Lethal Toxin Disrupts TCR Signaling in CD1d-Restricted NKT Cells Leading to Functional Anergy
por: Joshi, Sunil K., et al.
Publicado: (2009)

Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
por: Huang, Po-Lin, et al.
Publicado: (2023)

Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
por: Wang, Pengju, et al.
Publicado: (2018)

Correction: Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma
por: Lai, Jinzhi, et al.
Publicado: (2022)

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019)

The Role of GAB1 in Cancer
por: Pérez-Baena, Manuel Jesús, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rlsajeav5jl8ptj7jrr4sh7qss